Unknown

Dataset Information

0

Design of the randomized, placebo-controlled evolocumab for early reduction of LDL-cholesterol levels in patients with acute coronary syndromes (EVOPACS) trial.


ABSTRACT: Statins lower low-density lipoprotein cholesterol (LDL-C) and improve clinical outcomes in patients with atherosclerotic cardiovascular disease (CVD). Patients with acute coronary syndromes (ACS) often do not achieve LDL-C targets despite potent statin treatment, and have a particularly high risk of early recurrent events. Evolocumab, a proprotein convertase subtilisin/kexin type (PCSK9)-inhibitor resulting in rapid, marked LDL-C reduction, has been studied in hypercholesterolemic subjects without CVD and stabilized patients with CVD; the feasibility, safety, and efficacy of this treatment initiated in the acute phase of ACS remain unknown. We report the design of evolocumab for early reduction of LDL-cholesterol levels in patients with ACS (EVOPACS), a phase-3, multicenter, randomized, double-blind, placebo-controlled trial to assess the feasibility, safety, and LDL-C-lowering efficacy of evolocumab on top of atorvastatin 40?mg in patients with ACS. The primary endpoint is percent change in LDL-C from baseline to 8?weeks. Secondary endpoints are adverse events and serious adverse events. Against a background of beneficial cardiovascular effects of statins beyond LDL-C lowering and in view of preclinical evidence of similar effects of PCSK9 inhibition, the study will also address a variety of exploratory endpoints including the change in C-reactive protein and other inflammatory biomarkers; platelet reactivity; and occurrence of contrast-induced acute kidney injury and myocardial injury in patients undergoing cardiac catheterization. An intracoronary imaging sub-study will investigate the change from baseline in the lipid core burden index in non-culprit lesions, as assessed by serial near-infrared spectroscopy. Recruitment began in January 2018 and enrollment of 308 patients is planned.

SUBMITTER: Koskinas KC 

PROVIDER: S-EPMC6490138 | biostudies-literature | 2018 Dec

REPOSITORIES: biostudies-literature

altmetric image

Publications

Design of the randomized, placebo-controlled evolocumab for early reduction of LDL-cholesterol levels in patients with acute coronary syndromes (EVOPACS) trial.

Koskinas Konstantinos C KC   Windecker Stephan S   Buhayer Aliki A   Gencer Baris B   Pedrazzini Giovanni G   Mueller Christian C   Cook Stephan S   Muller Olivier O   Matter Christian M CM   Räber Lorenz L   Heg Dik D   Mach François F  

Clinical cardiology 20181126 12


Statins lower low-density lipoprotein cholesterol (LDL-C) and improve clinical outcomes in patients with atherosclerotic cardiovascular disease (CVD). Patients with acute coronary syndromes (ACS) often do not achieve LDL-C targets despite potent statin treatment, and have a particularly high risk of early recurrent events. Evolocumab, a proprotein convertase subtilisin/kexin type (PCSK9)-inhibitor resulting in rapid, marked LDL-C reduction, has been studied in hypercholesterolemic subjects witho  ...[more]

Similar Datasets

| S-EPMC4929378 | biostudies-literature
| S-EPMC9397913 | biostudies-literature
| S-EPMC10119028 | biostudies-literature
| S-EPMC10853845 | biostudies-literature
| S-EPMC4844254 | biostudies-other
| S-EPMC6489930 | biostudies-literature
| S-EPMC6258123 | biostudies-literature
| S-EPMC3138874 | biostudies-literature
| S-EPMC2500189 | biostudies-literature
| S-EPMC8241924 | biostudies-literature